Bristol Myers Squibb (BMS) has entered into a massive strategic collaboration with China’s Hengrui Pharma, a deal that underscores a growing trend of Western pharmaceutical giants … Read more
Congress is returning from a two-week recess to a legislative calendar dominated by a high-stakes health care agenda. At the center of the debate is the … Read more
The biotechnology sector is currently navigating a period of strategic realignment, characterized by a high volume of executive movement as companies pivot from early-stage research to … Read more
Europe is facing a systemic crisis in its life sciences sector, caught in a geopolitical pincer movement between the aggressive trade policies of the United States … Read more
The Food and Drug Administration has once again denied approval for an experimental treatment for advanced skin cancer developed by Replimune Group, marking a second setback … Read more
A coalition of Senate Democrats is moving to prioritize a comprehensive overhaul of the American health care system, focusing heavily on the persistent issue of rising … Read more
AllRock Bio has reached a critical milestone in its effort to treat severe cardiopulmonary diseases, announcing on April 9, 2026, that it has dosed the first … Read more
Steve Ubl, the long-time leader of the Pharmaceutical Research and Manufacturers of America, is stepping down as CEO of the industry’s most influential trade group. Ubl, … Read more
For many older adults, the simple act of walking while holding a conversation or counting backward is more than a casual activity—We see a complex neurological … Read more
Colorado lawmakers are considering a legislative effort to exempt orphan drugs from pricing limits, a move that could shield medications for rare diseases from the oversight … Read more
The Trump administration has launched a high-stakes effort to overhaul the American medical supply chain, imposing new tariffs on branded medications from companies that have not … Read more
The legal architecture of the United States’ recent trade offensive has shifted, but for the American corporate landscape, the dust has yet to settle. While a … Read more